Atty. Dkt. No. 040283-0197

REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application.

Respectfully submitted,

Date: January 18, 2002

By _____

Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

FOLEY & LARDNER
Customer Number: 22428
22428
PATENT TRADEMARK OFFICE
Telephone: (202) 672-5427
Facsimile: (202) 672-5399

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) [Use] **A method of neuroprotection or for treating cerebral ischaemia, central nervous system injury or eye diseases, comprising administering to a subject in need of such treatment an effective dose** of a compound of formula (I)



(I)

wherein:

R^1 is aryl;

R^2 is H, alkyl or aryl; and

R^3 is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof[, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases].

2. (Amended) A **method** [use] according to claim 1, wherein R^1 is a substituted or unsubstituted phenyl or naphthyl.

3. (Amended) A **method** [use] according to claim 1, [or 2] wherein R^1 has 1, 2 or 3 substituent groups.

4. (Amended) A **method** [use] according to claim 1, [2 or 3] wherein R^1 is chlorophenyl, fluorophenyl, (trifluoromethyl)phenyl, 3, 4-dichlorophenyl or 3, 4-difluorophenyl.

5. (Amended) A **method** [use] according to claim 1, [2, 3 or 4] wherein R^2 is hydrogen or methyl.

6. (Amended) A **method** [use] according to [any one of claims 1 to 5] **claim 1,** wherein R^3 is alkyl.

7. (Amended) A **method** [use] according to [any one of claims 1 to 5] **claim 1,** wherein R^3 is alkenyl, alkynyl, hydroxyalkyl or alkoxyalkyl.

8. (Amended) A **method** [use] according to [any preceding] claim **1,** wherein R^3 is allyl or propargyl.

9. (Amended) A **method** [use] according to [any one of claims 1 to 5] **claim 1,** wherein R^3 is unsubstituted saturated cyclic or acyclic hydrocarbyl.

10. (Amended) A **method** [use] according to claim 1 wherein the compound is selected from:

3-(4-chlorobenzyloxy)-N-(2-propenyl) azetidine-1-carboxamide,

3-(3,4-dichlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(3-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(4-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(4-fluorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide,

(R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide,

3-((3-chlorophenyl) methoxy)-azetidine-1-carboxamide, and

3-(1-(3-trifluoromethylphenyl)ethyloxy)-azetidine-1-carboxamide.

11. (Amended) A **method** [use] according to [any preceding] claim **1,** wherein said [medicament comprises] **compound is in combination with** a pharmaceutically acceptable carrier [and as active ingredient an effective amount of a compound of formula (I)].

12. (Amended) A **method** [use] according to claim 11, wherein said carrier comprises a cyclodextrin or an ether derivative thereof.

13. (Amended) A **method** [use] according to [any preceding] claim **11,** wherein [the medicament] **said carrier** further comprises a buffer system, an isotonizing agent and water.

14. (Amended) **A method** [Use] according to [any of preceding] claim **1,** wherein the compound of formula (I) is in combination with one or more additional drugs useful in neuroprotection or in the treatment of cerebral ischaemia, central nervous system injury or eye diseases, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.